India’s Jubilant Shakes Hands With Endo Pharma For Drug Discovery,
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal marks the sixth discovery and lead optimization deal for the firm in 18 months.
You may also be interested in...
AstraZeneca, Jubilant Biosys Join Hands For Leads In Neuroscience
MUMBAI - Collaborative research between Indian and multinational drug companies gained further ground as Jubilant Biosys signed an agreement with AstraZeneca for delivering novel drug candidates to strengthen its preclinical pipeline. Based out of Bangalore, Jubilant Biosys is the research arm of Jubilant Organosys
Amgen and India’s Jubilant In Drug Discovery Partnership
MUMBAI - Jubilant Biosys, a subsidiary of Indian contract research and manufacturing services provider Jubilant Organosys, has entered into a drug discovery partnership with Amgen to develop a portfolio of new drugs across various therapeutic areas
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.